Jan A. Burger
faculty.mdanderson.org
0000-0002-6177-7572
19 papers found
Refreshing results…
Molecular map of chronic lymphocytic leukemia and its impact on outcome
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL
Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia
Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies
New pieces in the BTKi resistance puzzle
Obinutuzumab: the more the merrier?
Missing publications? Search for publications with a matching author name.